Securities & Exchange Commission v. Cassava Sciences, Inc. et al

Track this case

Case Number:

1:24-cv-01150

Court:

Texas Western

Nature of Suit:

Securities/Commodities

Judge:

David A. Ezra

  1. April 03, 2026

    SEC Moves To Set Up $40M Investor Fund In Cassava Case

    The U.S. Securities and Exchange Commission asked a Texas federal court on Friday to establish a $40 million fund to potentially compensate investors harmed by a Texas biopharmaceutical company and two former executives' alleged misstatements about an Alzheimer's drug, following the company's 2024 settlement with the regulator.

  2. September 26, 2024

    SEC Fines Cassava $40M Over Alzheimer's Treatment Claims

    Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two of its former executives agreed to pay over $40 million to resolve U.S. Securities and Exchange Commission claims related to allegedly misleading statements about clinical trial results for a potential Alzheimer's disease therapeutic, the regulator announced on Thursday.